Camostat mesylate_product_DataBase

Bioactivity	Camostat mesylate (Camostat mesilate) is an orally active, synthetic serine protease inhibitor for chronic pancreatitis. Camostat mesylate, an inhibitor of TMPRSS2, shows antiviral activity against SARS-CoV-2. Camostat mesylate also inhibits the activity of prostasin, trypsin, and matriptase[1][2][3].
Invitro	Camostat mesylate (Camostat mesilate) inhibits both monocyte chemoattractant protein-1 (MCP-1) and TNF-α production from monocytes, and proliferation and MCP-1 production from PSCs[1].Camostat mesylate, a trypsin-like protease inhibitor, provides a potent (IC50=50 nM) and prolongs attenuation of ENaC function in human airway epithelial cell models that is reversible upon the addition of excess trypsin[3].
In Vivo	Camostat mesilate (30 mg/kg; p.o.; twice a day for 9 days) blocks the spread and pathogenesis of SARS-CoV in a pathogenic mouse model[4]. Animal Model:
Name	Camostat mesylate
CAS	59721-29-8
Formula	C21H26N4O8S
Molar Mass	494.52
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Reference	[1]. Gibo J, et al. Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. Lab Invest. 2005;85(1):75‐89. [2]. Uno Y. Camostat mesilate therapy for COVID-19 [published online ahead of print, 2020 Apr 29]. Intern Emerg Med. 2020;1‐2. [3]. Coote K, et al. Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J Pharmacol Exp Ther. 2009;329(2):764‐774. [4]. Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015;116:76‐84.

PeptideDB

Camostat mesylate

CAS: 59721-29-8 F: C21H26N4O8S W: 494.52